Stan Smith Acquires 33,333 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 33,333 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The stock was acquired at an average price of $1.50 per share, for a total transaction of $49,999.50. Following the completion of the transaction, the director now directly owns 1,305,059 shares of the company’s stock, valued at approximately $1,957,588.50. This trade represents a 2.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

MAIA Biotechnology Price Performance

Shares of MAIA stock opened at $1.80 on Friday. The company has a market capitalization of $47.09 million, a price-to-earnings ratio of -1.30 and a beta of 0.20. MAIA Biotechnology, Inc. has a one year low of $1.40 and a one year high of $4.31. The company’s fifty day moving average price is $1.79 and its 200-day moving average price is $2.07.

Institutional Trading of MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 39,057 shares of the company’s stock, valued at approximately $77,000. Jane Street Group LLC owned 0.15% of MAIA Biotechnology at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.